Pharma BD Deal Intelligence
Collapse: GSK's $700M upfront, $2.2B neurodegeneration bet fell apart on both fronts — latozinemab missed its co-primary endpoint in Phase 3 INFRONT-3 for FTD-GRN, triggering a 49% Alector workforce cut, while AL101 was scrapped after PROGRESS-AD stopped for futility.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GlaxoSmithKline is paying $700 million upfront for a partnership on Alector's lead neurodegeneration assets, latozinemab and AL101, in a deal that could be…
GlaxoSmithKline has agreed to pay South San Francisco's Alector $700 million upfront and as much as $1.5 billion more in milestones for the global rights to…
IDMC determined PROGRESS-AD unlikely to meet its primary endpoint of slowing disease progression; development of nivisnebart for early Alzheimer's discontinued.
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
GSK and Alector entered a global development and commercialization collaboration (announced July 22, 2021; agreement effective August 17, 2021 after HSR clearance) for two progranulin-elevating monoclonal antibodies, latozinemab (AL001) and AL101/GSK4527226 (nivisnebart), targeting neurodegenerative diseases. Alector received $700M upfront ($500M in Q3 2021, $200M in Q1 2022) and was eligible for up to $1.5B in milestones, with 50/50 US profit share and ex-US tiered double-digit royalties. The collaboration thesis has since collapsed: latozinemab missed the clinical co-primary endpoint in the Phase 3 INFRONT-3 trial in FTD-GRN (topline October 21, 2025) and its development was discontinued, prompting Alector to cut ~49% of its workforce; nivisnebart was then discontinued in early Alzheimer's disease after the Phase 2 PROGRESS-AD trial was stopped for futility following an IDMC interim analysis (April 29, 2026). Both lead assets of the collaboration have now failed in the clinic.
3K US cases/yr · $18.0B Global neurodegeneration therapeutics market 2021 · $700M Alector upfront cash payment
The GSK-Alector collaboration targets neurodegenerative diseases via progranulin-elevating monoclonal antibodies, with the lead indication frontotemporal dementia caused by progranulin (GRN) gene mutations (FTD-GRN). FTD affects approximately 60,000 U.S. patients with FTD-GRN representing about 5-10% of cases (~3,000-6,000 U.S. patients), making it a rare disease eligible for orphan drug designation. The broader neurodegenerative target market includes Alzheimer's disease (~6.5 million U.S. patients), ALS (~30,000 U.S. patients), and Parkinson's disease (~1 million U.S. patients). FTD-GRN is mechanistically tractable because heterozygous GRN loss-of-function mutations halve circulating progranulin protein, providing a clear biomarker-driven dosing target. Latozinemab (AL001) is the lead asset with FDA Breakthrough Therapy designation (Sep 2021), Fast Track, and Orphan Drug designations, in pivotal Phase 3 INFRONT-3 trial. Alector partnered with GSK to share development costs and global commercial economics — 50/50 U.S. profit share and ex-U.S. tiered double-digit royalties. WAC pricing benchmarks for orphan neurology biologics include nusinersen (Spinraza, $750K year one) and onasemnogene abeparvovec (Zolgensma, $2.1M one-time), framing FTD-GRN as a premium-priced rare disease launch. Alector collected $700M upfront and is eligible for up to $1.5B in milestones.
The progranulin-axis and broader neurodegeneration competitive landscape is rapidly maturing. Anti-amyloid mAbs include lecanemab (Leqembi, Eisai/Biogen, FDA approved Jan 2023), donanemab (Kisunla, Lilly, FDA approved July 2024), and aducanumab (Aduhelm, Biogen, accelerated approval 2021, withdrawn 2024). Anti-tau monoclonal antibodies include semorinemab (RG6100, Genentech/AC Immune), zagotenemab (Lilly, discontinued 2021), bepranemab (UCB), and gosuranemab (Biogen, discontinued). ALS programs include tofersen (Qalsody, Biogen, FDA approved April 2023 for SOD1-ALS) and AMX0035/Relyvrio (Amylyx, FDA approved 2022, withdrawn 2024). Direct progranulin-elevating competitors include Denali's PTV:PGRN (DNL593, transferrin receptor brain shuttle, Phase 1) and Vesper Bio. Parkinson's disease programs include cinpanemab (anti-alpha-synuclein, Biogen, discontinued 2021) and prasinezumab (Roche/Prothena, Phase 2 readout 2024). Alector's progranulin-elevating mAb mechanism (latozinemab) is differentiated by sortilin-targeted GRN receptor blockade enabling endogenous PGRN restoration. GSK gains a precision-medicine neurology franchise anchor and Alector retains a second AL101 program with broader Alzheimer's/Parkinson's potential.
Collaboration & License Agreement (signed July 1, 2021) became effective August 17, 2021 after expiry of the HSR antitrust waiting period; $500M of the $700M upfront paid in Q3 2021, $200M in Q1 2022.
Latozinemab (AL001) missed the clinical co-primary endpoint of slowing FTD-GRN progression in the 96-week Phase 3 INFRONT-3 trial despite raising plasma progranulin. Alector discontinued the OLE/continuation study and cut ~49% of its workforce.
The second collaboration asset, nivisnebart (AL101/GSK4527226), had its Phase 2 PROGRESS-AD trial in early Alzheimer's disease discontinued after an IDMC interim futility analysis concluded the trial was unlikely to meet its primary endpoint. Both collaboration assets have now failed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Alector, Inc. (this deal) | 2021 | $2.2B | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2021 deals · GlaxoSmithKline plc deals · Neurology deals